Cargando…

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

INTRODUCTION: The first cardiovascular safety trial in the sodium-glucose co-transporter-2 (SGLT2) inhibitor drug class, the Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial, demonstrated significant cardiovascular risk reduction with empagliflozin. It...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGovern, Andrew, Feher, Michael, Munro, Neil, de Lusignan, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380507/ https://www.ncbi.nlm.nih.gov/pubmed/28324484 http://dx.doi.org/10.1007/s13300-017-0254-7

Ejemplares similares

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
por: McGovern, Andrew, et al.
Publicado: (2017)

Does Renal Function or Heart Failure Diagnosis Affect Primary Care Prescribing for Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes?
por: Hinton, William, et al.
Publicado: (2020)

How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol
por: Hinton, William, et al.
Publicado: (2019)

Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
por: Hinton, William, et al.
Publicado: (2021)

Sodium–glucose co‐transporter‐2 inhibitor cardiovascular outcome trials and generalizability to English primary care
por: Hinton, W., et al.
Publicado: (2020)

Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)
por: Feher, Michael, et al.
Publicado: (2022)

Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK
por: McGovern, Andrew, et al.
Publicado: (2016)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
por: Kalra, Sanjay, et al.
Publicado: (2015)

Adverse Effect Profile and Effectiveness of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i) - A Prospective Real-world Setting Study
por: Gill, Harmandeep Kaur, et al.
Publicado: (2019)

Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience
por: Dass, Ashwitha S., et al.
Publicado: (2019)

Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol
por: Hinton, William, et al.
Publicado: (2018)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
por: Donnan, Jennifer R, et al.
Publicado: (2019)

Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan
por: Ito, Yuichiro, et al.
Publicado: (2019)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
por: Vivian, Eva M
Publicado: (2014)

Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
por: Kalra, Sanjay
Publicado: (2014)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States
por: Aggarwal, Rahul, et al.
Publicado: (2021)

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
por: Mascolo, Annamaria, et al.
Publicado: (2022)

Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
por: Hinton, William, et al.
Publicado: (2019)

Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality
por: Feher, Michael, et al.
Publicado: (2021)

Erratum to: Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
por: Kalra, Sanjay
Publicado: (2015)

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
por: Saad, Muhammad, et al.
Publicado: (2018)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
por: Neumiller, Joshua J
Publicado: (2014)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes, Bryce C, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)

Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review
por: Lopaschuk, Gary D., et al.
Publicado: (2020)

Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
por: Lee, Soo Yong, et al.
Publicado: (2020)

Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients
por: Balan, Irina, et al.
Publicado: (2021)

Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability
por: Chen, Yung‐Chih, et al.
Publicado: (2021)

Real‐time imaging of sodium glucose transporter (SGLT1) trafficking and activity in single cells
por: Ghezzi, Chiara, et al.
Publicado: (2017)

Clinical And Biochemical Outcomes Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors In Type 2 Diabetes Mellitus Patients
por: Saleem, Muhammad, et al.
Publicado: (2021)

Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus
por: Ito, Yuichiro, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
por: Hendryx, Michael, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
por: Krishnan, Anoushka, et al.
Publicado: (2023)

Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus
por: Geist, Barbara Katharina, et al.
Publicado: (2023)

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus
por: Bays, Harold
Publicado: (2013)

Fournier’s Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Life-Threatening Complications
por: Kasbawala, Kinjal, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bt5fmin01l5nkh5f84dbenrhmg